[1] |
MURTAZA G, KARIM S, AKRAM MR, et al. Caffeic acid phenethyl ester and therapeutic potentials[J]. Biomed Res Int, 2014, 2014: 145342. DOI: 10.1155/2014/145342.
|
[2] |
OLGIERD B, KAMILA Z, ANNA B, et al. The pluripotent activities of caffeic acid phenethyl ester[J]. Molecules, 2021, 26(5): 1335. DOI: 10.3390/molecules26051335.
|
[3] |
LI M, WANG XF, SHI JJ, et al. Caffeic acid phenethyl ester inhibits liver fibrosis in rats[J]. World J Gastroenterol, 2015, 21(13): 3893-3903. DOI: 10.3748/wjg.v21.i13.3893.
|
[4] |
YANG N, SHI JJ, WU FP, et al. Caffeic acid phenethyl ester up-regulates antioxidant levels in hepatic stellate cell line T6 via an Nrf2-mediated mitogen activated protein kinases pathway[J]. World J Gastroenterol, 2017, 23(7): 1203-1214. DOI: 10.3748/wjg.v23.i7.1203.
|
[5] |
HAZARI Y, BRAVO-SAN PEDRO JM, HETZ C, et al. Autophagy in hepatic adaptation to stress[J]. J Hepatol, 2020, 72(1): 183-196. DOI: 10.1016/j.jhep.2019.08.026.
|
[6] |
KOUROUMALIS E, VOUMVOURAKI A, AUGOUSTAKI A, et al. Autophagy in liver diseases[J]. World J Hepatol, 2021, 13(1): 6-65. DOI: 10.4254/wjh.v13.i1.6.
|
[7] |
ALLAIRE M, RAUTOU PE, CODOGNO P, et al. Autophagy in liver diseases: Time for translation?[J]. J Hepatol, 2019, 70(5): 985-998. DOI: 10.1016/j.jhep.2019.01.026.
|
[8] |
ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4): 875. DOI: 10.3390/cells9040875.
|
[9] |
KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
|
[10] |
LEVINE B, KROEMER G. Biological functions of autophagy genes: a disease perspective[J]. Cell, 2019, 176(1-2): 11-42. DOI: 10.1016/j.cell.2018.09.048.
|
[11] |
WANG H, LIU Y, WANG D, et al. The upstream pathway of mTOR-mediated autophagy in liver diseases[J]. Cells, 2019, 8(12): 1597. DOI: 10.3390/cells8121597.
|
[12] |
LEE KW, THIYAGARAJAN V, SIE HW, et al. Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells[J]. J Nutr Biochem, 2014, 25(9): 903-913. DOI: 10.1016/j.jnutbio.2014.04.001.
|
[13] |
PARK M, KIM YH, WOO SY, et al. Tonsil-derived mesenchymal stem cells ameliorate CCl4-induced liver fibrosis in mice via autophagy activation[J]. Sci Rep, 2015, 5: 8616. DOI: 10.1038/srep08616.
|
1. | 王德志,胡海洋,郭长华,宋磊. 钆贝葡胺核磁共振增强与CT多期增强扫描对肝硬化伴小肝癌诊断的对比研究. 中西医结合肝病杂志. 2021(05): 449-451 . ![]() | |
2. | 赵锦洪,彭德新,杨智利,徐仁根,刘岚,龚良庚. 普美显和马根维显MRI增强对肝硬化背景下小肝癌诊断的对比研究. 江西医药. 2021(07): 915-918 . ![]() | |
3. | 罗竹人,汪艳,蔡琳婷,郭春英. 钆塞酸二钠增强MRI与增强CT对肝脏局灶性病变的诊断价值. 中国卫生标准管理. 2020(24): 66-70 . ![]() | |
4. | 李艳丽,解玥,汤奉琼,马婷,赵惠菊. 肝脏特异性造影剂(钆塞酸二钠)的应用体会. 智慧健康. 2020(33): 85-86 . ![]() | |
5. | 沈丽荣,张立云,戴灼南. 肝胆期钆塞酸二钠磁共振动态增强扫描在肝硬化结节与小肝癌的鉴别诊断中的应用价值. 广州医科大学学报. 2019(02): 44-47 . ![]() | |
6. | 陈翔,王苇. 普美显动态增强联合DWI对强化特征不典型肝癌和肝内复发灶的诊断价值. 临床医学研究与实践. 2018(21): 150-151 . ![]() | |
7. | 董丽伟,王飞,罗是是,赵应满,陈峰,李建军. 3.0T磁共振钆塞酸二钠增强扫描对肝硬化患者肝脏再生结节良恶性质的鉴别诊断价值. 中国医药导报. 2018(31): 127-130 . ![]() | |
8. | 王莉莉,李俊峰,窦郁,郭顺林,雷军强. MR功能成像对肝细胞癌微血管侵犯的评估价值. 临床肝胆病杂志. 2018(12): 2681-2684 . ![]() |